ChAdOx1.85A+MVA85A*
ChAdOx1.85A is a simian adenoviral vector expressing Antigen 85A. MVA85A is a modified vaccinia virus Ankara expressing Antigen 85A. The target route of administration for ChAdOx1.85A is aerosol, and intramuscular for MVA85A.
Read MoreDAR-901^
DAR-901 is an inactivated whole cell vaccine derived from a non-tuberculous mycobacterium and represents a scalable manufacturing process for SRL172.
Read MoreAEC/BC02
AEC/BC02 is made from the Ag85b protein and ESAT6-CFP10 protein expressed by recombinant Escherichia coli as the active antigen component (AEC) and the complex adjuvant system (BC02) composed of cytosine guanine dinucleotide (BCG-cpg-DNA) and aluminum hydroxide of BCG.
Read MoreImmuvac (also known as MIP)
ID93+GLA-SE (also known as QTP101)
ID93+GLA-SE (also known as QTP101) consists of the active pharmaceutical ingredient, a recombinant protein ID93, and an adjuvant, GLA-SE. The ID93 recombinant protein is composed of the four Mtb antigens Rv3619, Rv1813, Rv3620, and Rv2608 linked in tandem. GLA is a molecule similar to synthetic monophosphoryl lipid A (MPL®) as a TLR4 agonist.
Read More